

Study Number: I16011HR
Test Type: TOX
Route: Oral Gavage
Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary
Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine
CAS Number: 95737-68-1

Date Report Requested: 03/26/2025
Time Report Requested: 16:17:22
Lab: Burleson Research Technologies

Study Number: I16011HR
Study Sex: Female
PWG Approval Date: See web page for date of PWG Approval
Version: v1.7.2
Stat Version: 2022.10.13S

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 7

Treatment Groups (mg/kg)

Phase Day	0			62.5			125			250		
	Wt (g)	N		Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	190.3 ± 2.6	10		185.8 ± 2.2	97.6	10	193.6 ± 3.4	101.7	10	195.2 ± 4.8	102.6	10
SD7	200.0 ± 3.0	10		193.1 ± 3.8	96.6	10	200.2 ± 4.0	100.1	10	199.1 ± 5.1	99.6	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 7

Phase Day	Treatment Groups (mg/kg)								
	500			0.6/0.2 mg/kg DEX			Naive		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	191.5 ± 2.3	100.6	10	187.1 ± 7.6	98.3	10	190.8 ± 2.3		5
SD7	195.4 ± 2.5	97.7	10	173.9 ± 3.9 **	86.9	9	206.6 ± 3.2		5

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 8

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	189.1 ± 3.8	10	194.8 ± 4.4	103.0	10	192.3 ± 3.5	101.7	10	192.1 ± 2.6	101.6	10
SD7	200.3 ± 3.7	10	207.4 ± 3.9	103.5	10	206.8 ± 3.6	103.2	10	206.0 ± 4.2	102.8	10
SD8	196.3 ± 4.1	10	204.9 ± 3.7	104.4	10	203.9 ± 3.6	103.9	10	205.0 ± 4.0	104.4	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 8

Phase Day	Treatment Groups (mg/kg)					
	500			0.6/0.2 mg/kg DEX		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	193.5 ± 4.8	102.3	10	188.7 ± 4.3	99.8	10
SD7	204.9 ± 4.9	102.3	10	170.6 ± 4.2 **	85.2	10
SD8	203.2 ± 4.7	103.5	10	165.4 ± 4.0 **	84.3	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 10

Treatment Groups (mg/kg)

Phase Day	0			62.5			125			250		
	Wt (g)	N		Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	191.8 ± 4.3	10		194.1 ± 3.8	101.2	10	192.1 ± 3.2	100.2	10	186.3 ± 2.4	97.1	10
SD7	204.8 ± 4.3	10		208.9 ± 4.0	102.0	10	208.5 ± 4.7	101.8	10	200.4 ± 2.8	97.9	10
SD10	209.6 ± 4.3 *	10		210.8 ± 3.8	100.6	10	214.5 ± 5.6	102.3	10	201.7 ± 2.4	96.2	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 10

Phase Day	Treatment Groups (mg/kg)					
	500			0.6/0.2 mg/kg DEX		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	186.5 ± 2.1	97.2	10	186.3 ± 3.7	97.1	10
SD7	200.2 ± 2.1	97.8	10	171.4 ± 4.1 **	83.7	10
SD10	199.9 ± 2.4	95.4	10	167.8 ± 4.7 **	80.1	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 14

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	193.3 ± 3.9	10	194.2 ± 3.0	100.5	10	190.4 ± 3.8	98.5	10	187.2 ± 4.1	96.8	10
SD7	207.3 ± 5.8	10	209.4 ± 3.7	101.0	10	206.5 ± 3.7	99.6	10	201.5 ± 4.2	97.2	10
SD14	214.8 ± 5.6	10	213.9 ± 4.1	99.6	10	212.8 ± 2.8	99.1	10	212.1 ± 5.1	98.7	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 14

Phase Day	Treatment Groups (mg/kg)					
	500			0.6/0.2 mg/kg DEX		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	191.6 ± 3.7	99.1	10	188.7 ± 2.5	97.6	10
SD7	209.1 ± 5.5	100.9	10	171.8 ± 2.4 **	82.9	10
SD14	213.5 ± 4.6	99.4	10	172.5 ± 2.2 **	80.3	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burlison Research Technologies

Females: Terminal Day 28

Treatment Groups (mg/kg)

Phase Day	0		62.5			125			250		
	Wt (g)	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	190.3 ± 2.7	10	191.7 ± 2.9	100.7	10	188.2 ± 3.0	98.9	10	192.4 ± 3.7	101.1	10
SD7	202.9 ± 2.7	10	204.4 ± 3.2	100.7	10	203.1 ± 3.2	100.1	10	206.6 ± 3.4	101.8	10
SD14	216.5 ± 5.0	10	209.0 ± 4.0	96.5	10	212.4 ± 3.6	98.1	10	212.8 ± 2.8	98.3	10
SD21	223.4 ± 4.0	10	224.9 ± 4.1	100.7	10	221.8 ± 3.2	99.3	10	225.8 ± 3.8	101.1	10
SD28	233.0 ± 3.8	10	229.1 ± 4.0	98.3	10	231.6 ± 4.1	99.4	10	233.7 ± 3.2	100.3	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

Females: Terminal Day 28

Phase Day	Treatment Groups (mg/kg)					
	500			0.6/0.2 mg/kg DEX		
	Wt (g)	% of CNTL	N	Wt (g)	% of CNTL	N
SD0	190.4 ± 4.1	100.1	10	189.3 ± 3.7	99.5	10
SD7	202.2 ± 4.7	99.7	10	173.4 ± 3.4 **	85.5	10
SD14	213.1 ± 5.1	98.4	10	175.0 ± 3.2 **	80.8	10
SD21	226.5 ± 5.3	101.4	10	173.7 ± 3.4 **	77.8	10
SD28	233.2 ± 4.9	100.1	10	175.1 ± 4.0 **	75.2	10

Study Number: I16011HR

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

I04: Mean Body Weight Summary

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

Date Report Requested: 03/26/2025

Time Report Requested: 16:17:22

Lab: Burleson Research Technologies

LEGEND

Weights are displayed as mean \pm SEM, with N as the number of animals.

Statistical analysis performed by Jonckheere (trend) and Williams/Dunnett (pairwise) tests. The positive control group (0.6/0.2 mg/kg DEX) was excluded from trend test.

Statistical analysis for the positive control group (0.6/0.2 mg/kg DEX) compared to the vehicle control group was performed using the t-test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

SEM = Standard Error of the Mean

DEX = Dexamethazone (0.6 mg/kg study days 3-8 and 0.2 mg/kg study days 9-27)

SD = Study Day

The Naive group was not included in the statistical analysis.

Naive animals were included to show that work practices did not inadvertently infect the animals.

**** END OF REPORT ****